MedTrace Logo

Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot Study

NCT05950711 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-08-11

No results posted yet for this study

Summary

The purpose of this study is to assess the feasibility of combining IV ketamine, a rapid acting antidepressant, with a course of Mindfulness-Based Cognitive Therapy (MBCT), for the initial and maintenance treatment of depression.

Conditions

Interventions

OTHER

Combination use of MBCT and IV Ketamine

Group with Major Depression who will receive a single dose of IV Ketamine embedded within a course of MBCT.

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-30
Primary Completion
2026-11-30
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05950711 on ClinicalTrials.gov